Cytek Biosciences: Growth Over Profit Will Pay Off In The Long Term
2025-09-09 12:25:16 ET
Investment Thesis
I grant Cytek Biosciences ( CTKB ) a buy rating. I am of the opinion that the company has the tools to generate profit in the upcoming years. The net losses reported by Cytek are due to the firm's prioritization of growth over profit. However, its losses are relatively small. For instance, in 2023, it reported $12 million in net losses, its worst year since 2020. Cytek has significant resources to fund its operations. In Q2 2025, its liquid assets were $262.02 million. With these resources, and assuming that Cytek will continue to report net losses similar to those observed since 2023, the company can fund its operations for several years....
Read the full article on Seeking Alpha
For further details see:
Cytek Biosciences: Growth Over Profit Will Pay Off In The Long Term
NASDAQ: CTKB
CTKB Trading
0.11% G/L:
$4.53 Last:
436,531 Volume:
$4.38 Open:
